Dishman Carbogen Amcis Limited’s CHF 25 Million Swiss Expansion Set to Boost ADC Manufacturing by FY27
By Ankur Chandra | Updated at: Jun 7, 2025 12:18 AM IST
Mumbai, June 6, 2025: Dishman Carbogen Amcis Limited (NSE: DCAL | BSE: 540701) has confirmed that its wholly-owned Swiss subsidiary, CARBOGEN AMCIS AG, has entered into a co-investment agreement valued at over CHF 25 million with a long-term Japanese client. The agreement is geared towards enhancing the company’s ADC (Antibody-Drug Conjugate) manufacturing capabilities at its Aarau and Neuland facilities in Switzerland.
On 6 June 2025, at 15:58 pm, the stock declined by ₹5.30 (-1.94%) to close at ₹268.10. It traded between ₹266.05 and ₹279.80 during the day. The 52-week range spans ₹145.15 to ₹307.98. With a volume of 774,517 shares and a VWAP of ₹270.41, the market cap stood at ₹4,203 crore. Despite a high TTM PE of 1,276.67, the P/B remains low at 0.74. The stock remains volatile with a beta of 1.57.
Major Dual-Site Expansion to Meet Rising ADC Market Demand
As part of the agreement, both the Aarau and Neuland sites will undergo major infrastructure enhancements to expand production of drug linkers – key components in ADC therapies used for targeted oncology treatments.
Key Enhancements and Timelines
| Site | Planned Upgrades | Completion Timeline |
|---|---|---|
| Aarau | Installation of 850-litre reactors and 0.4 m² agitated filter dryers | Q1 FY27 |
| Neuland | Similar equipment with supporting auxiliary systems | Q3 FY27 |
These investments aim to significantly boost production volumes while ensuring adherence to global cGMP (current Good Manufacturing Practice) standards.
A Continuation of Strategic Collaboration
This latest expansion builds upon an earlier collaboration between CARBOGEN AMCIS and the same Japanese client, which began with a site extension initiative in Bubendorf in April 2021. The renewed partnership underscores the shared trust and sustained technical alignment between the two companies.
Stephan Fritschi, CEO of CARBOGEN AMCIS AG, remarked,
“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds.”
Carl Baker, Vice President of the Drug Substance Business Unit, added,
“These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence required for highly potent APIs.”
About CARBOGEN AMCIS AG and Dishman Group
CARBOGEN AMCIS AG is a globally recognised CDMO (Contract Development and Manufacturing Organization), specialising in the production of highly potent APIs and advanced pharmaceutical compounds. The company operates out of multiple locations in Switzerland, France, the UK, the Netherlands, and China.
Its parent company, Dishman Carbogen Amcis Limited, is headquartered in Ahmedabad, India, and acts as a vital outsourcing partner for the international pharmaceutical industry, offering end-to-end development and manufacturing solutions across Europe, China, and India.
REF: https://nsearchives.nseindia.com/corporate/DCAL_06062025144602_Pressrelease06062025.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
